Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTRESS: Balixafortide + Eribulin in HER2- Metastatic Breast Cancer
NCT03786094Phase 3Terminated
- Sponsor
- Spexis AG
- Start
- May 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules, Modified Peptides
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of balixafortide in breast cancer (2 arms), sponsored by Spexis AG. Primary endpoints: Progression Free Survival (2nd Line+ Population) and Progression Free Survival (3rd Line+ Population). Started May 2019; status: terminated.
02
Drugs
balixafortide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03786094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786094.